ALAMEDA, Calif.--(BUSINESS WIRE)--Embryome Sciences, Inc., a wholly owned subsidiary of BioTime, Inc. (OTCBB:BTIM), announced today the license of a portfolio of patents and patent applications from Advanced Cell Technology, Inc. (“ACT”) relating to induced pluripotent stem cells (“iPS”) and embryonic stem cell differentiation technology. The license is for the commercialization of products in human therapeutic and diagnostic product markets.
